Effects of cisplatin combined with gemcitabine chemotherapy on patients with advanced non-small cell lung cancer

Abstract

Objective To investigate the 3-year survival rate of patients with advanced non-small cell lung cancer who received cisplatin combined with gemcitabine chemotherapy. Methods A retrospective study was performed on 86 cases of patients with advanced non-small cell lung cancer who were admitted from March 2014 to March 2015.Patients were randomly divided into the gefitinib combined treatment group, 43 cases, including 23 male and 20 female, aged(58.7±10.93)years old, ranged from 44 to 73 years old; the gemcitabine combined treatment group, 43 cases, including 25 male and 18 female, aged(61.8±7.44)years old, ranged from 46 to 72 years old.The gemcitinib combined treatment group of patients was treated with cisplatin combined chemotherapy, and the gemcitabine combined treatment group was treated with gemcitabine combined cisplatin chemotherapy.The clinical efficacy, incidence of adverse reactions, recurrence rate, metastasis rate, survival rate and quality of life of the patients in the two groups were compared. Results The total effective rate[86.1%(37/43)]in the gemcitabine combined treatment group was higher than that in the gemcitabine combined treatment group[69.8%(30/43)], and the incidence of adverse reactions [6.9%(3/43)] in the gemcitabine combined treatment group was lower than that in the gemcitabine combined treatment group [18.4%(8/43)], with statistically significant differences(P<0.05). The recurrence rate and metastasis rate of patients in the gemcitabine combined treatment group [4.6%(2/43), 2.3%(1/43)] were lower than those in the gemcitabine combined treatment group [16.3%(7/43), 14.0%(6/43)]; the survival rate [55.8%(24/43)] in the gemcitabine combination treatment group was higher than that in the gemcitabine combination treatment group [34.9%(15/43)]; the mean survival time(22.23±1.24)months in the gemcitabine combined treatment group was longer than that in the gemcitabine combined treatment group(18.23±1.34)months, and the difference was statistically significant(P<0.05). The scores of physiology, daily life, cognition, emotion, social function and overall health status in the gemcitabine combined treatment group were all higher than those in the gemcitabine combined treatment group during the follow-up period, and the differences were statistically significant(P<0.05). Conclusion Cisplatin combined with gefitinib in the treatment of advanced NSCLC is more effective, which can achieve better survival rate during the follow-up, and the side effects of chemotherapy will not be increased during the treatment, so the safety is higher. Key words: Cisplatin; Gefitinib; Advanced non-small cell lung cancer; Chemotherapy; Survival rates